Histiocytosis Clinical Trial
Official title:
Enquête épidémiologique Sur la prévalence et le Pronostic de l'Histiocytose Langerhansienne Pulmonaire de l'Adulte en France
The long-term outcomes of adult patients with pulmonary Langerhans cell histiocytosis (PLCH), particularly survival, is largely unknown. This is the first prospective study in the field evaluating the long-term outcomes of PLCH patients. This french countrywide registry-based study included a large cohort of PLCH patients followed for a sufficiently long period to address risk factors of long-term outcomes of PLCH patients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01049854 -
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
|
Phase 2 | |
Recruiting |
NCT05915208 -
Histiocytic Disorder Follow-up Study
|
||
Recruiting |
NCT04437381 -
Molecular Targets for the Treatment of Histiocytosis
|
||
Terminated |
NCT01050439 -
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
|
Phase 2 | |
Active, not recruiting |
NCT00145626 -
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT05803629 -
Characterizing Histiocytosis With 68Ga-FAPI PET/CT
|
N/A | |
Terminated |
NCT02012231 -
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
|
Phase 1 | |
Completed |
NCT01225718 -
Ceftriaxone in Non-neutropenic Fever
|
N/A | |
Active, not recruiting |
NCT03127709 -
A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis
|
||
Recruiting |
NCT05786924 -
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers
|
Phase 1 | |
Recruiting |
NCT04943211 -
Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
|
Phase 3 | |
Recruiting |
NCT04943198 -
Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
|
Phase 2 | |
Recruiting |
NCT04943224 -
Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
|
Phase 2 |